Board of Directors

Marios Fotiadis – Chairman

Marios has more than 20 years of experience in venture capital and private equity in the healthcare and life sciences sectors. He is currently a member of the Board of Directors of IRRAS (Sweden), Senté (US), Klaris SA (Luxembourg), and Opocrin SpA (Italy). He has worked at TVM Capital, Advent International, and SG Capital Partners. Marios has an MBA from Columbia University. 

Kleanthis G, Xanthopoulos

Kleanthis is a serial biotechnology entrepreneur with over two decades of experience in the biotechnology and pharmaceutical research industries as an executive, company founder, chief executive officer, investor and board member. Dr. Xanthopoulos has founded five companies, introduced three life science companies to NASDAQ and financed and brokered numerous creative strategic alliance and partnership deals with large pharmaceutical partners.

Dr. Xanthopoulos was formerly the CEO of IRRAS AB, and Chairman of Stork Capital Life Sciences which focuses on building and investing in innovative biotechnology companies. Dr. Xanthopoulos participated in The Human Genome Project as a Section Head of the National Human Genome Research Institute from 1995 to 1997. Prior to this, he was an Associate Professor at the Karolinska Institute, Stockholm, Sweden. An Onassis Foundation scholar, Dr. Xanthopoulos received his B.Sc. in Biology with honors from Aristotle University of Thessaloniki, Greece, and received both his M.Sc. in Microbiology and Ph.D. in Molecular Biology from the University of Stockholm, Sweden. Dr. Xanthopoulos has over 45 peer-reviewed publications and several issued patents.In addition to his role at Shoreline Biosciences, Dr. Xanthopoulos is member of the board of directors of IRRAS AB, Connect Biopharma, (NASDAQ: CNTB), Zosano Pharma, Inc., (NASDAQ: ZSAN), and is the co-founder and a member of the board of directors of privately held Sente Inc. Previously, he served on the boards of LDO sp.a. (Milan, Italy), Odyssey Therapeutics, Anadys Pharmaceuticals and Regulus Therapeutics.

Michel Pettigrew

Michel Pettigrew boasts an impressive career spanning more than four decades in the Pharmaceutical Industry. His extensive track record includes roles as Executive Chairman of SEVER Life Sciences BV, Executive Chairman of Ferring Holding Inc., and 14 years as President of Ferring Holding. Prior to this, Michel held several senior positions at Bristol-Myers Squibb. Currently, he is a Board member of Hovione AG, a family-owned CDMO, AgoraCare, a Geneva-based medtech startup and IRRAS Holding Inc.

Olof Clausson

Olof Clausson, a US corporate lawyer and former partner of Latham & Watkins LLP. Based in London, Olof was one of Europe’s leading capital markets lawyers. Among many high-profile engagements, he advised the Government of Singapore Corporation (GIC) on its CHF 13 billion investment in UBS. He assisted Ericsson on its SEK 30 billion rights offering, and Nordea on its €3 billion rights offering. Between 2016 and 2019, he acted on 5 of Europe’s 20 largest IPOs. Currently, he is a Board member of IRRAS Holding Inc.

Salameh Sweis

Salameh has more than 20 years of experience in private equity and finance. He is a founding partner of Levant Capital and its CEO. Salameh is currently a member of the Board of Directors of several of Levant Capital’s portfolio companies. Salameh worked at Goldman Sachs in New York and has a BS from Rensselaer Polytechnic Institute.